Marinus Pharmaceuticals, Inc (MRNS)

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Marinus Pharma (NASDAQ:MRNS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know ...

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing ...

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gainers Intercept Pharmaceuticals (NASDAQ:ICPT) stock increased by 41.2% to $22.86 during Thursday's pre-market ...

Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is ...

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

Celebrations may be in order for Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders, with the analysts...

Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported ...

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value ...

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q4 earnings results on Monday, March 21, 2022 at 07:15 AM. Here's ...

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at ...

Biotech stocks rebounded along with the broader market in the week endingMarch 18, as risk appetite returned. Multiple conference ...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS)shares are trading higher by 25.0% at $10.72 after the company announced the FDA has ...

The U.S. health regulator has approved Marinus Pharmaceuticals Inc's lead drug to treat seizures associated with a rare genetic disorder in patients two years of age and older, the company said on Friday, sending its shares soaring around 36%. The oral drug, which will be sold under the brand name Ztalmy, is for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy. Ztalmy is expected to be commercially available in the United States in July following scheduling by the U.S. Drug Enforcement Administration, Marinus said in a statement.

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder

Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AeroVironment, Inc. (AVAV), where a total of 5,511 contracts have traded so far, representing approximately 551,100 underlying shares..

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?